TD Asset Management Inc Has $80.31 Million Stake in Cencora, Inc. (NYSE:COR)

TD Asset Management Inc trimmed its stake in shares of Cencora, Inc. (NYSE:COR) by 9.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 356,464 shares of the company’s stock after selling 35,785 shares during the period. TD Asset Management Inc owned approximately 0.18% of Cencora worth $80,311,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Rise Advisors LLC acquired a new position in shares of Cencora during the first quarter worth approximately $25,000. Legacy Bridge LLC acquired a new position in shares of Cencora during the first quarter worth approximately $27,000. New Millennium Group LLC acquired a new position in shares of Cencora during the second quarter worth approximately $26,000. TCTC Holdings LLC acquired a new position in shares of Cencora during the first quarter worth approximately $29,000. Finally, TFO Wealth Partners LLC acquired a new position in shares of Cencora during the first quarter worth approximately $30,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Trading Down 0.6 %

COR opened at $234.93 on Friday. The firm’s fifty day moving average is $232.25 and its two-hundred day moving average is $233.18. The company has a debt-to-equity ratio of 3.93, a quick ratio of 0.55 and a current ratio of 0.89. The firm has a market cap of $46.86 billion, a PE ratio of 25.70, a price-to-earnings-growth ratio of 1.57 and a beta of 0.44. Cencora, Inc. has a twelve month low of $172.41 and a twelve month high of $247.66.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.18 by $0.16. Cencora had a net margin of 0.65% and a return on equity of 266.60%. The company had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. During the same quarter in the prior year, the firm earned $2.92 earnings per share. The firm’s revenue was up 10.8% compared to the same quarter last year. Equities research analysts anticipate that Cencora, Inc. will post 13.61 EPS for the current year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were given a dividend of $0.51 per share. This represents a $2.04 annualized dividend and a dividend yield of 0.87%. The ex-dividend date of this dividend was Friday, August 9th. Cencora’s dividend payout ratio is 22.32%.

Insider Transactions at Cencora

In other news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the sale, the executive vice president now owns 10,948 shares of the company’s stock, valued at $2,656,970.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Cencora news, CEO Steven H. Collis sold 10,755 shares of Cencora stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total value of $2,388,900.60. Following the sale, the chief executive officer now directly owns 285,088 shares in the company, valued at approximately $63,323,746.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Silvana Battaglia sold 1,473 shares of Cencora stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the sale, the executive vice president now owns 10,948 shares in the company, valued at $2,656,970.12. The disclosure for this sale can be found here. Insiders sold 4,450,399 shares of company stock valued at $1,070,392,799 over the last quarter. Corporate insiders own 15.80% of the company’s stock.

Analysts Set New Price Targets

COR has been the topic of several analyst reports. JPMorgan Chase & Co. increased their price objective on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. StockNews.com upgraded shares of Cencora from a “buy” rating to a “strong-buy” rating in a report on Friday, August 2nd. Wells Fargo & Company increased their price objective on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a report on Thursday, August 1st. Leerink Partners restated an “outperform” rating and issued a $275.00 price objective on shares of Cencora in a report on Thursday, June 27th. Finally, Robert W. Baird cut their price objective on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a report on Friday. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $258.13.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.